PM4Onco: personalized medicine for oncology Effective use of data for molecular tumor boards
Onkologie (Heidelberg, Germany)
2024
30
10
898-904
Gene editing of hematopoietic stem cells restores T-cell response in familial hemophagocytic lymphohistiocytosis.
J Allergy Clin Immunol
2024
153
1
243-255.e14
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies.
Eur J Cancer
2025
216
Primary Results of Patients with Genitourinary Malignancies Presented at a Molecular Tumor Board.
Urol Int
2024
108
5
383-391
Expert-Guided Large Language Models for Clinical Decision Support in Precision Oncology.
JCO Precision Oncology
2024
8
The Technical University of Munich Cancer Center - elevating cancer treatment through science.
Mol Cancer
2024
23
1
The German Network for Personalized Medicine to enhance patient care and translational research.
Nat Med
2023
29
6
1298-1301
Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients.
npj Precis Oncol
2023
7
1
Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors.
npj Precis Oncol
2024
8
1